Pharmacogenomics of Multiple Sclerosis: A Systematic Review

Keli Hočevar, Smiljana Ristić, Borut Peterlin, Keli Hočevar, Smiljana Ristić, Borut Peterlin

Abstract

Background: Over the past two decades, various novel disease-modifying drugs for multiple sclerosis (MS) have been approved. However, there is high variability in the patient response to the available medications, which is hypothesized to be partly attributed to genetics. Objectives: To conduct a systematic review of the current literature on the pharmacogenomics of MS therapy. Methods: A systematic literature search was conducted using PubMed/MEDLINE database searching for articles investigating a role of genetic variation in response to disease-modifying MS treatments, published in the English language up to October 9th, 2018. PRISMA guidelines for systematic reviews were applied. Studies were included if they investigated response or nonresponse to MS treatment defined as relapse rate, by expanded disability status scale score or based on magnetic resonance imaging. The following data were extracted: first author's last name, year of publication, PMID number, sample size, ethnicity of patients, method, genes, and polymorphisms tested, outcome, significant associations with corresponding P-values and confidence intervals, response criteria, and duration of the follow-up period. Results: Overall, 48 articles published up to October 2018, evaluating response to interferon-beta, glatiramer acetate, mitoxantrone, and natalizumab, met our inclusion criteria and were included in this review. Among those, we identified 42 (87.5%) candidate gene studies and 6 (12.5%) genome-wide association studies. Existing pharmacogenomic evidence is mainly based on the results of individual studies, or on results of multiple studies, which often lack consistency. In recent years, hypothesis-free approaches identified novel candidate genes that remain to be validated. Various study designs, including the definition of clinical response, duration of the follow-up period, and methodology as well as moderate sample sizes, likely contributed to discordances between studies. However, some of the significant associations were identified in the same genes, or in the genes involved in the same biological pathways. Conclusions: At the moment, there is no available clinically actionable pharmacogenomic biomarker that would enable more personalized treatment of MS. More large-scale studies with uniform design are needed to identify novel and validate existing pharmacogenomics findings. Furthermore, studies investigating associations between rare variants and treatment response in MS patients, using next-generation sequencing technologies are warranted.

Keywords: Systematic review; multiple sclerosis; personalized treatment; pharmacogenomics; treatment response.

Figures

Figure 1
Figure 1
Flow diagram of identification and selection of studies.

References

    1. Sawcer S, Franklin RJM, Ban M. Multiple sclerosis genetics. Lancet Neurol. (2014) 13:700–9. 10.1016/S1474-4422(14)70041-9
    1. Belbasis L, Bellou V, Evangelou E, Ioannidis JPA, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. (2015) 14:263–73. 10.1016/S1474-4422(14)70267-4
    1. Carlson RJ, Doucette JR, Nazarali AJ. Current developments in pharmacogenomics of multiple sclerosis. Cell Mol Neurobiol. (2014) 34:1081–5. 10.1007/s10571-014-0095-0
    1. Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E, et al. . HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology (2001) 57:1976–9. 10.1212/WNL.57.11.1976
    1. Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, et al. . Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol. (2006) 59:344–52. 10.1002/ana.20740
    1. Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO. Comparative pharmacogenetics of multiple sclerosis: IFN-beta versus glatiramer acetate. Pharmacogenomics (2014) 15:679–85. 10.2217/pgs.14.26
    1. Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, et al. . A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol. (2015) 78:115-27. 10.1002/ana.24429
    1. Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, et al. . Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. (2018) 14:75–93. 10.1038/nrneurol.2017.171
    1. Ransohoff R, Hafler D, Lucchinetti C. Multiple sclerosis - a quiet revolution. Nat Rev Neurol. (2015) 11:134–42. 10.1038/nrneurol.2015.14
    1. Tsareva E, Kulakova O, Boyko A, Favorova O. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs. Pharmacogenet Genomics (2016) 26:103–15. 10.1097/FPC.0000000000000194
    1. Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, Fernandez M, et al. . Genome-wide scan of 500 000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. (2009) 66:972–8. 10.1001/archneurol.2009.150
    1. Duquette P, Giacomini PS, Bhan V, Hohol M, Schecter R. Balancing early aggression against risk of progression in multiple sclerosis. Can J Neurol Sci. (2015) 43:33–43. 10.1017/cjn.2015.302
    1. Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, et al. . PANTHER version 11: expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. (2017) 45:D183–9. 10.1093/nar/gkw1138
    1. McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics (2013) 10:2–18. 10.1007/s13311-012-0163-4
    1. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology (2002) 58:S3–9. 10.1212/WNL.58.8_suppl_4.S3
    1. Villoslada P, Barcellos LF, Rio J, Begovich AB, Tintore M, Sastre-Garriga J, et al. . The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol. (2002) 130:194–201. 10.1016/S0165-5728(02)00215-1
    1. Fernández O, Fernández V, Mayorga C, Guerrero M, León A, Tamayo JA, et al. . HLA class II and response to interferon-beta in multiple sclerosis. Acta Neurol Scand (2005) 112:391–4. 10.1111/j.1600-0404.2005.00415.x
    1. Comabella M, Fernández-Arquero M, Río J, Guinea A, Fernández M, Cenit MC, et al. . HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. J Neuroimmunol. (2009) 210:116–9. 10.1016/j.jneuroim.2009.01.012
    1. Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, et al. . Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. (2011) 233:168–74. 10.1016/j.jneuroim.2010.10.038
    1. Samadzadeh S, Tabibian E, Sabokbar T, Shakoori A, Dehgolan SR, Armaki SA, et al. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients. J Neurol Sci. (2015) 352:37–40. 10.1016/j.jns.2015.03.004
    1. Sriram U, Barcellos LF, Villoslada P, Rio J, Baranzini SE, Caillier S, et al. . Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun. (2003) 4:147–52. 10.1038/sj.gene.6363946
    1. Leyva L, Fernández O, Fedetz M, Blanco E, Fernández VE, Oliver B, et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol. (2005) 163:165–71. 10.1016/j.jneuroim.2005.02.010
    1. Carmona O, Masuet C, Alía P, Moral E, Alonso-Magdalena L, Casado V, et al. . Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis. Eur Neurol. (2011) 65:132–7. 10.1159/000323982
    1. Guerrero AL, Tejero MA, Gutiérrez F, Martín-Polo J, Iglesias F, Laherran E, et al. . Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis. Neurol (English Ed (2011) 26:137–142. 10.1016/j.nrl.2010.06.003
    1. Vandenbroeck K, Alloza I, Swaminathan B, Antigüedad A, Otaegui D, Olascoaga J, et al. . Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes Immun. (2011) 12:40–45. 10.1038/gene.2010.46
    1. Sellebjerg F, Søndergaard HB, Koch-Henriksen N, Sørensen PS, Oturai AB. Prediction of response to interferon therapy in multiple sclerosis. Acta Neurol Scand. (2014) 130:268–75. 10.1111/ane.12269
    1. Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, et al. . NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Mult Scler J. (2018) 24:1507–10. 10.1177/1352458517739137
    1. Malhotra S, Rio J, Urcelay E, Nurtdinov R, Bustamante MF, Fernandez O, et al. . NLRP3 inflammasome is associated with the response to IFN-beta in patients with multiple sclerosis. Brain (2015) 138:644–52. 10.1093/brain/awu388
    1. Weinstock-Guttman B, Tamaño-Blanco M, Bhasi K, Zivadinov R, Ramanathan M. Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients. J Neuroimmunol. (2007) 182:236–9. 10.1016/j.jneuroim.2006.10.011
    1. Cénit MDC, Blanco-Kelly F, de las Heras V, Bartolomé M, de la Concha EG, Urcelay E, et al. . Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler (2009) 15:913–7. 10.1177/1352458509106509
    1. Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, Lechner-Scott J, Urcelay E, et al. IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. J Neuroimmunol. (2011) 239:101–4. 10.1016/j.jneuroim.2011.08.004
    1. Cunningham S, Graham C, Hutchinson M, Droogan A, O'Rourke K, Patterson C, et al. . Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther. (2005) 78:635-46. 10.1016/j.clpt.2005.08.018
    1. Sayad A, Ghafouri-Fard S, Omrani MD, Noroozi R, Taheri M. Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients. Neurol Sci. (2017) 38:1093–9. 10.1007/s10072-017-2935-4
    1. Kulakova OG, Tsareva EY, Boyko AN, Shchur SG, Gusev EI, Lvovs D, et al. . Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients. Pharmacogenomics (2012) 13:1689–700. 10.2217/pgs.12.161
    1. Karam RA, Rezk NA, Amer MM, Fathy HA. Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy. IUBMB Life (2016) 68:727–34. 10.1002/iub.1530
    1. Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BMJ, et al. . Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis. Genes Immun. (2011) 12:466–72. 10.1038/gene.2011.18
    1. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, et al. . Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol. (2008) 65:337–44. 10.1001/archneurol.2008.47
    1. Bustamante MF, Morcillo-Suarez C, Malhotra S, Rio J, Leyva L, Fernandez O, et al. . Pharmacogenomic study in patients with multiple sclerosis: responders and nonresponders to IFN-β. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e154. 10.1212/NXI.0000000000000154
    1. O'Doherty C, Favorov A, Heggarty S, Graham C, Favorova O, Ochs M, et al. . Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics (2009) 10:1177–86. 10.2217/pgs.09.41
    1. Wergeland S, Beiske A, Nyland H, Hovdal H, Jensen D, Larsen JP, et al. . IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol. (2005) 12:171–175. 10.1111/j.1468-1331.2004.01102.x
    1. Ristić S, Starčević Cizmarević N, Lavtar P, Lovrečić L, Perković O, Sepčić J, et al. . Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients. Pharmacogenet Genomics (2017) 27:232–5. 10.1097/FPC.0000000000000283
    1. Torbati S, Karami F, Ghaffarpour M, Zamani M. Association of CD58 polymorphism with multiple sclerosis and response to interferon ß therapy in a subset of Iranian population. Cell J. 16:506–13. 10.22074/cellj.2015.505
    1. Malhotra S, Morcillo-Suárez C, Nurtdinov R, Rio J, Sarro E, Moreno M, et al. . Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment. Eur J Neurol. (2013) 20:1390–7. 10.1111/ene.12193
    1. López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, et al. . Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients. PLoS O NE(2013) 8:e62540. 10.1371/journal.pone.0062540
    1. Martínez A, De Las Heras V, Mas Fontao A, Bartolomé M, De La Concha EG, Urcelay E, et al. . An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol. (2006) 173:196–9. 10.1016/j.jneuroim.2005.12.002
    1. Alvarez-Lafuente R, Blanco-Kelly F, Garcia-Montojo M, Martínez A, De Las Heras V, Dominguez-Mozo MI, et al. . CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Mult Scler. (2011) 17:513–20. 10.1177/1352458510393263
    1. Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, et al. . HLA genes as modifiers of response to IFN-beta-1a therapy in relapsing-remitting multiple sclerosis. Pharmacogenomics (2016) 17:489–98. 10.2217/pgs.16.2
    1. Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, et al. . Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients. Pharmacogenomics J. (2012) 12:238–45. 10.1038/tpj.2011.14
    1. Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, et al. . Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics J. (2017) 17:312–8. 10.1038/tpj.2016.20
    1. Clarelli F, Liberatore G, Sorosina M, Osiceanu AM, Esposito F, Mascia E, et al. . Pharmacogenetic study of long-term response to interferon-beta treatment in multiple sclerosis. Pharmacogenomics J. (2017) 17:84–91. 10.1038/tpj.2015.85
    1. Hasson T, Kolitz S, Towfic F, Laifenfeld D, Bakshi S, Beriozkin O, et al. . Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. J Neuroimmunol. (2016) 290:84–95. 10.1016/j.jneuroim.2015.11.020
    1. Dhib-Jalbut S, Valenzuela RM, Ito K, Kaufman M, Ann Picone M, Buyske S. HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis. Mult Scler Relat Disord. (2013) 2:340–8. 10.1016/j.msard.2013.02.005
    1. Kulakova O, Bashinskaya V, Kiselev I, Baulina N, Tsareva E, Nikolaev R, et al. . Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci. Pharmacogenomics (2017) 18:1563–74. 10.2217/pgs-2017-0058
    1. Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E, et al. . Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics (2007) 17:657–66. 10.1097/FPC.0b013e3281299169
    1. Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV, et al. . Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Pharmacogenomics (2012) 13:43–53. 10.2217/pgs.11.136
    1. Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, et al. . A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Med. (2017) 9:1–15. 10.1186/s13073-017-0436-y
    1. Auricchio F, Scavone C, Cimmaruta D, Di Mauro G, Capuano A, Sportiello L, et al. . Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf. (2017) 16:1359–71. 10.1080/14740338.2017.1388371
    1. Cotte S, Von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK, et al. . ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain (2009) 132:2517–30. 10.1093/brain/awp164
    1. Grey Née Cotte S, Salmen Née Stroet A, von Ahsen N, Starck M, Winkelmann A, Zettl UK, et al. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. J Neuroimmunol. (2015) 278:277–9. 10.1016/j.jneuroim.2014.11.017
    1. Alexoudi A, Zachaki S, Stavropoulou C, Gavrili S, Spiliopoulou C, Papadodima S, et al. . Possible implication of GSTP1 and NQO1 polymorphisms on natalizumab response in multiple sclerosis. Ann Clin Lab Sci. (2016) 46:586–91.
    1. Whirl-Carrillo M, McDonogh E, Herbet J, Gong L, Sangkuhl K, Thotn C, et al. . Pharmacogenomics knowledge for personlized medicine. Clin Pharmacol Ther. (2012) 92:414–7. 10.1038/clpt.2012.96
    1. Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen Per. Immunogenicity of interferon beta: differences among products. J Neurol. (2004) 251 (Suppl. 2):II15–II24. 10.1007/s00415-004-1204-7
    1. Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, et al. . Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology (2011) 77:835–43. 10.1212/WNL.0b013e31822c90d7
    1. Sbardella E, Tomassini V, Gasperini C, Bellomi F, Cefaro LA, Morra VB, et al. . Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study. BMC Neurol. (2009) 9:54. 10.1186/1471-2377-9-54
    1. Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermueller J, Stadler PF, et al. . HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am J Hum Genet. (2008) 83:219–27. 10.1016/j.ajhg.2008.07.006
    1. Buck D, Cepok S, Hoffmann S, Grummel V, Jochim A, Berthele A, et al. . Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol. (2011) 68:480–7. 10.1001/archneurol.2011.65
    1. Núñez C, Cénit MC, Alvarez-Lafuente R, Río J, Fernández-Arquero M, Arroyo R, et al. . HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis. J Med Genet. (2014) 51:395–400. 10.1136/jmedgenet-2014-102348
    1. Link J, Ryner ML, Fink K, Hermanrud C, Lima I, Brynedal B, et al. . Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS ONE (2014) 9:e90479. 10.1371/journal.pone.0090479
    1. van Baarsen LGM, Vosslamber S, Tijssen M, Baggen JMC, van der Voort LF, Killestein J, et al. . Pharmacogenomics of interferon-β therapy in multiple sclerosis: baseline IFN signature determines phamacological differences between patients. PLoS ONE (2008) 3:e1927. 10.1371/journal.pone.0001927
    1. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, et al. . A type i interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis. Brain (2009) 132:3353–65. 10.1093/brain/awp228
    1. Goertsches RH, Zettl UK, Hecker M. Sieving treatment biomarkers from blood gene-expression profiles: A pharmacogenomic update on two types of multiple sclerosis therapy. Pharmacogenomics (2011) 12:423–32. 10.2217/pgs.10.190
    1. Rudick RA, Rani MRS, Xu Y, Lee JC, Na J, Shrock J, et al. . Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS ONE (2011) 6:e19262. 10.1371/journal.pone.0019262
    1. Parnell GP, Gatt PN, McKay FC, Schibeci S, Krupa M, Powell JE, et al. . Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. Mult Scler J. (2014) 20:675–85. 10.1177/1352458513507819
    1. Moreno-Torres I, González-García C, Marconi M, García-Grande A, Rodríguez-Esparragoza L, Elvira V, et al. . Immunophenotype and transcriptome profile of patients with multiple sclerosis treated with fingolimod: Setting up a model for prediction of response in a 2-year translational study. Front Immunol. (2018) 9:1693. 10.3389/fimmu.2018.01693
    1. Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, Koczan D, et al. . Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS ONE (2011) 6:e29648. 10.1371/journal.pone.0029648
    1. Martire S, Navone ND, Montarolo F, Perga S, Bertolotto A. A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. J Neuroimmunol. (2016) 292:34–9. 10.1016/j.jneuroim.2016.01.010
    1. Beck H, Schwarz G, Schröter CJ, Deeg M, Baier D, Stevanovic S, et al. . Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol. (2001) 31:3726–36. 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>;2-O
    1. Río J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. (2009) 5:553–60. 10.1038/nrneurol.2009.139
    1. Nelson MR, Wegmann D, Ehm MG, Kessner D, St P, Verzilli C, et al. NIH Public Access. (2015) 337:100–104. 10.1126/science.1217876

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir